You are here
Generic Version of Neurontin Approved by FDA
Gabapentin Tablets are indicated for the management of postherpetic neuralgia in adults. Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy and is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 - 12 years.
According to Jim Meehan, Vice President of Sales and Marketing for RPI, "We are pleased to receive this final approval for Gabapentin Tablets. We will now focus on maximizing the value of this formulation to the company that will have a positive impact on our performance for the balance of this year. Ranbaxy will begin shipping this affordable generic alternative immediately."
Source: Ranbaxy Pharmaceuticals Inc.